Edition:
India

Lipocine Inc (LPCN.OQ)

LPCN.OQ on NASDAQ Stock Exchange Capital Market

3.56USD
2:29am IST
Change (% chg)

$-0.01 (-0.28%)
Prev Close
$3.57
Open
$3.57
Day's High
$3.62
Day's Low
$3.55
Volume
19,520
Avg. Vol
34,328
52-wk High
$5.32
52-wk Low
$3.15

Summary

Name Age Since Current Position

Mahesh Patel

57 2014 Chairman of the Board, President, Chief Executive Officer

Morgan Brown

47 2013 Chief Financial Officer, Executive Vice President

Gregory Bass

2017 Executive Vice President, Chief Commercial Officer

Stephen Hill

59 2014 Lead Independent Director

Jeffrey Fink

57 2014 Director

Richard Ono

62 2014 Director

John Higuchi

47 2013 Non-Executive Director

Biographies

Name Description

Mahesh Patel

Dr. Mahesh V. Patel, Ph.D., is Chairman of the Board, President, Chief Executive Officer of Lipocine Inc. He has served as Company's President and Chief Executive Officer since 1997 and as a member of Company's Board of Directors since 1997. Dr. Patel has more than 25 years of experience in strategic planning, technology assessment / development, technical management and product research and development in the area of drug discovery support, drug delivery and product line extensions. Prior to co-founding Lipocine in 1997, he led drug delivery research and development at Pharmacia and Upjohn. Dr. Patel received a B.Pharm from Karnataka University in India, a M.S. in Physical Pharmacy at the University of Cincinnati and a Ph.D. in Pharmaceutics from the University of Utah.

Morgan Brown

Mr. Morgan R. Brown CPA, has been appointed as Chief Financial Officer, Executive Vice President of Lipocine Inc., with effect from September 16, 2013. Mr. Brown has more than 20 years of financial and accounting experience, including over 13 years in financial management of life science companies. Most recently, Mr. Brown was the CFO at Innovus Pharmaceuticals, Inc. (OTCBB: INNV). Previously he was the CFO of World Heart Corporation (formerly NASDAQ: WHRT) and Lifetree Clinical Research and the Vice President, Finance and Treasurer of NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) . Before NPS Pharmaceuticals Mr. Brown was a Senior Manager at KPMG LLP. Mr. Brown is a Certified Public Accountant in Utah, and he earned a master’s degree in business administration from the University of Utah and a bachelor’s degree in accounting from Utah State University.

Gregory Bass

Mr. Gregory Bass is Executive Vice President, Chief Commercial Officer of the Company. Mr. Bass has over 20 years of experience in pharmaceutical and biopharmaceutical sales, marketing and market access with a consistent track record of improving operating performance and delivering value across a broad range of leadership roles in therapeutic categories at Pfizer and Johnson & Johnson. Mr. Bass received his bachelor's degree in Biology from Brandeis University in Waltham, MA.

Stephen Hill

Dr. Stephen Anthony Hill, M.D., is Lead Independent Director of the Lipocine Inc. Dr. Hill has significant executive management experience in the therapeutics industry. Dr. Hill currently serves as a director, President and Chief Executive Officer of Targacept Inc. (TRGT). He has over 20 years of industry experience, having served previously as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc., where he led an organization of over 1,200 employees until its acquisition by Abbott Laboratories in 2010, and ArQule, Inc., where he led a successful transition for the company from a fee-for-service discovery chemistry operation to a company with a proprietary clinical-stage pipeline. Prior to ArQule, Dr. Hill held several leadership positions with F. Hoffmann-La Roche Ltd., including global head of clinical development. He is a Fellow of the Royal College of Surgeons of England and holds degrees in medicine and surgery from St. Catherine’s College at Oxford University.

Jeffrey Fink

Mr. Jeffrey A. Fink is Director of the Lipocine Inc. Mr. Fink has over 20 years of finance and strategy experience within the life science and healthcare industry. Mr. Fink is currently the managing director of Gambel Oaks Advisors, LLC, a strategic and financial advisory firm dedicated to the life sciences and allied industries. Mr. Fink spent over twenty years in the investment banking industry advising life science clients in the U.S. and Europe on the full range of financing and strategic advisory assignments. He was head of Healthcare Investment Banking for Robert W. Baird & Co. in Chicago until 2007, and prior to that was a partner in the Healthcare Group at Dresdner Kleinwort Wasserstein (the successor firm to Wasserstein Perella) and head of Mergers and Acquisitions for Prudential Vector Healthcare Securities International, Inc., a dedicated biotechnology and life sciences investment bank. Mr. Fink’s advisory clients have included Schering AG, Genentech, Boehringer Ingleheim, F. Hoffman LaRoche, Ltd., the Ares Serrono Group and Celgene Pharmaceuticals. Mr. Fink has been involved in over fifty public and private equity financings, and he has advised on over $3 billion in mergers, acquisitions and strategic alliances. Mr. Fink also serves on the Boards of Navigen, Inc. and Metalosensors. Mr. Fink has an MBA in finance and accounting from the University of Michigan and a BA in economics and business administration from Kalamazoo College.

Richard Ono

Dr. Richard Dana Ono is Director of the Lipocine Inc. Dr. Ono brings 30 years of experience managing public and private life science companies. Throughout his career, he has been engaged in strategic planning, product management, technology acquisition, and commercial development for multiple early stage life science companies and has been involved in a number of key advances for the industry. Dr. Ono has founded several biotech companies in the U.S., including IntraImmune Therapies, Inc., a biotechnology company which he sold to Abgenix, Inc. (now Amgen), along with several successful early stage biotech companies in the Boston area. Currently, he is a venture partner at VIMAC Ventures LLC. Dr. Ono received his AB in Earth & Planetary Sciences from The Johns Hopkins University and his AM and PhD in Biology from Harvard University, where he also completed a program in business administration.

John Higuchi

Mr. John W. Higuchi is a Non-Executive Director of Lipocine Inc. Since 2003, Mr. Higuchi has served as President and Chief Executive Officer of Aciont Inc., an ocular therapeutics company. From 1997 to 2003, Mr. Higuchi served as our Vice President of Business Development and Corporate Treasurer. Mr. Higuchi also has worked for the American Chemical Society. Mr. Higuchi received a B.S. in Chemistry from Hope College and an M.B.A. and Master of Science in Information Systems from The George Washington University. We believe that Mr. Higuchi’s business development and management experience in the therapeutics industry, together with his significant knowledge of our company obtained while serving as a director of our company, will greatly benefit our Board of Directors.

Basic Compensation

Name Fiscal Year Total

Mahesh Patel

966,397

Morgan Brown

486,999

Gregory Bass

--

Stephen Hill

--

Jeffrey Fink

--

Richard Ono

--

John Higuchi

--
As Of  31 Dec 2014

Options Compensation